Cargando…

Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms

BACKGROUND: Juvenile myelomonocytic leukaemia (JMML) and chronic myelomonocytic leukaemia (CMML) are myelodysplastic myeloproliferative (MDS/MPN) neoplasms with unfavourable prognosis and without effective chemotherapy treatment. Trabectedin is a DNA minor groove binder acting as a modulator of tran...

Descripción completa

Detalles Bibliográficos
Autores principales:	Romano, Michela, Della Porta, Matteo Giovanni, Gallì, Anna, Panini, Nicolò, Licandro, Simonetta Andrea, Bello, Ezia, Craparotta, Ilaria, Rosti, Vittorio, Bonetti, Elisa, Tancredi, Richard, Rossi, Marianna, Mannarino, Laura, Marchini, Sergio, Porcu, Luca, Galmarini, Carlos M, Zambelli, Alberto, Zecca, Marco, Locatelli, Franco, Cazzola, Mario, Biondi, Andrea, Rambaldi, Alessandro, Allavena, Paola, Erba, Eugenio, D'Incalci, Maurizio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5294481/ https://www.ncbi.nlm.nih.gov/pubmed/28072764 http://dx.doi.org/10.1038/bjc.2016.424

Ejemplares similares

Trabectedin and Plitidepsin: Drugs from the Sea that Strike the Tumor Microenvironment
por: Galmarini, Carlos M., et al.
Publicado: (2014)

Mechanism of action of trabectedin in desmoplastic small round cell tumor cells
por: Uboldi, S., et al.
Publicado: (2017)

Trabectedin, a drug acting on both cancer cells and the tumour microenvironment
por: D'Incalci, M, et al.
Publicado: (2014)

A systems biology approach to investigate the mechanism of action of trabectedin in a model of myelomonocytic leukemia
por: Mannarino, L, et al.
Publicado: (2018)

Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin
por: Colmegna, B, et al.
Publicado: (2015)

Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin
por: Bello, Ezia, et al.
Publicado: (2019)

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
por: Belgiovine, Cristina, et al.
Publicado: (2017)

Correction: Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin
por: Bello, Ezia, et al.
Publicado: (2020)

New activities for the anti-tumor agent trabectedin: taking two birds with one stone
por: D'Incalci, Maurizio, et al.
Publicado: (2013)

Trabectedin: A drug from the sea that strikes tumor-associated macrophages
por: Allavena, Paola, et al.
Publicado: (2013)

Editorial: Trabectedin, lurbinectedin, and other marine-derived anticancer alkaloids on solid cancer: Mechanisms of action, clinical impact, and future perspectives
por: Zambelli, Alberto, et al.
Publicado: (2023)

Effects of the Anti-Tumor Agents Trabectedin and Lurbinectedin on Immune Cells of the Tumor Microenvironment
por: Allavena, Paola, et al.
Publicado: (2022)

Trabectedin modulates the senescence-associated secretory phenotype and promotes cell death in senescent tumor cells by targeting NF-κB
por: Camorani, Simona, et al.
Publicado: (2018)

Trabectedin and Lurbinectedin Extend Survival of Mice Bearing C26 Colon Adenocarcinoma, without Affecting Tumor Growth or Cachexia
por: Aquila, Giorgio, et al.
Publicado: (2020)

A Systems Biology Approach to Characterize the Regulatory Networks Leading to Trabectedin Resistance in an In Vitro Model of Myxoid Liposarcoma
por: Uboldi, Sarah, et al.
Publicado: (2012)

Inhibition of tumor‐associated macrophages by trabectedin improves the antitumor adaptive immunity in response to anti‐PD‐1 therapy
por: Belgiovine, Cristina, et al.
Publicado: (2021)

Regional and temporal heterogeneity of epithelial ovarian cancer tumor biopsies: implications for therapeutic strategies
por: Paracchini, Lara, et al.
Publicado: (2016)

DNA Damage Response and Immune Defense
por: Nastasi, Claudia, et al.
Publicado: (2020)

Important functional role of the protein osteopontin in the progression of malignant pleural mesothelioma
por: Digifico, Elisabeth, et al.
Publicado: (2023)

A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin
por: Grosso, Federica, et al.
Publicado: (2012)

Liquid Biopsy in the Clinical Management of High-Grade Serous Epithelial Ovarian Cancer—Current Use and Future Opportunities
por: Paracchini, Lara, et al.
Publicado: (2021)

Tumor treating fields affect mesothelioma cell proliferation by exerting histotype-dependent cell cycle checkpoint activations and transcriptional modulations
por: Mannarino, Laura, et al.
Publicado: (2022)

Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity
por: Herzog, J., et al.
Publicado: (2016)

Targeted Mutational Analysis of Circulating Tumor DNA to Decipher Temporal Heterogeneity of High-Grade Serous Ovarian Cancer
por: Paracchini, Lara, et al.
Publicado: (2022)

Synergistic Effect of Trabectedin and Olaparib Combination Regimen in Breast Cancer Cell Lines
por: Ávila-Arroyo, Sonia, et al.
Publicado: (2015)

Time dependence of the in vitro cytotoxicity of hexamethylmelamine and its metabolites.
por: D'Incalci, M., et al.
Publicado: (1980)

Synergism between 5-fluorouracil and N-methylformamide in HT29 human colon cancer line.
por: Laudonio, N., et al.
Publicado: (1990)

Mechanism of cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cells in vitro and modulation of the drug activity by folic or folinic acid.
por: Erba, E., et al.
Publicado: (1994)

Role of membrane folate-binding protein in the cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cell lines in vitro.
por: Sen, S., et al.
Publicado: (1996)

HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance
por: Loria, Rossella, et al.
Publicado: (2018)

Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents
por: Colella, G, et al.
Publicado: (1999)

The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus
por: Vázquez, Ramiro, et al.
Publicado: (2016)

A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma
por: Gadducci, Angiolo, et al.
Publicado: (2018)

Effect of Aplidin in acute lymphoblastic leukaemia cells
por: Erba, E, et al.
Publicado: (2003)

Treatment with inhibitors of polyamine biosynthesis, which selectively lower intracellular spermine, does not affect the activity of alkylating agents but antagonizes the cytotoxicity of DNA topoisomerase II inhibitors.
por: Desiderio, M. A., et al.
Publicado: (1997)

The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
por: Ordóñez, José Luis, et al.
Publicado: (2015)

PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models
por: Morosi, Lavinia, et al.
Publicado: (2021)

α-Bromoacryloyl derivative of distamycin A (PNU 151807): a new non-covalent minor groove DNA binder with antineoplastic activity
por: Marchini, S, et al.
Publicado: (1999)

Mitozolomide activity on human cancer cells in vitro.
por: Erba, E., et al.
Publicado: (1986)

Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer
por: Colombo, Nicoletta, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1p5b9kaib4om5oj5f4l7l4slic